Clinical Trial: FDA-Approved CBD Formulation Reduces Post-Operative Opioid Consumption Following Knee Replacement Surgery

New York, NY: Knee replacement patients administered 400 mg of the FDA-approved plant-derived CBD prescription medicine Epidiolex experience less postoperative pain and require fewer opioids, according to placebo-controlled data published in The Journal of Pain.

A team of investigators affiliated with the Pain Prevention Research Center in New York assessed the opioid-sparing potential of Epidiolex in 36 patients who had undergone bilateral total knee arthroplasty. Study participants received four doses of either 400 mg of Epidiolex, 800mg of Epidiolex, or a placebo. Patients’ cumulative opioid intake and pain levels were assessed at 72 hours.

Researchers reported that patients who consumed 400 mg doses of Epidiolex experienced significant benefits as compared to those receiving either the higher dose or the placebo. They also reported improvements in their sleep quality.

They determined, “Patients receiving 400 mg CBD had lower postoperative opioid consumption, reduced pain scores at rest and with movement, and fewer rescue analgesic interventions compared to placebo, whereas 800 mg CBD did not demonstrate similar opioid-sparing effects.”

The study’s authors concluded: “These findings … provide preliminary support for a potential therapeutic signal at moderate CBD doses. … Collectively, this pilot study establishes clinically relevant rationale for continued evaluation of CBD as a component of multi-model perioperative pain management, with particular attention to identifying dosing ranges that balance efficacy and tolerability.”

Full text of the study, “Effects of cannabidiol oral solution in patients undergoing bilateral total knee arthroplasty: a randomized, controlled, parallel, triple blind, pilot study,” appears in The Journal of Pain.